Compare CACC & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CACC | PRAX |
|---|---|---|
| Founded | 1972 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 7.1B |
| IPO Year | 1996 | 2020 |
| Metric | CACC | PRAX |
|---|---|---|
| Price | $633.09 | $315.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 15 |
| Target Price | $505.00 | ★ $572.13 |
| AVG Volume (30 Days) | 177.8K | ★ 514.9K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 83.00 | N/A |
| EPS | ★ 12.40 | N/A |
| Revenue | ★ $2,317,200,000.00 | N/A |
| Revenue This Year | $91.73 | N/A |
| Revenue Next Year | $3.58 | $7,758.26 |
| P/E Ratio | $51.28 | ★ N/A |
| Revenue Growth | ★ 7.16 | N/A |
| 52 Week Low | $401.90 | $37.25 |
| 52 Week High | $668.86 | $366.52 |
| Indicator | CACC | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 58.92 | 49.37 |
| Support Level | $529.10 | $307.93 |
| Resistance Level | $668.86 | $343.96 |
| Average True Range (ATR) | 19.73 | 19.48 |
| MACD | -3.56 | -1.64 |
| Stochastic Oscillator | 44.02 | 25.30 |
Credit Acceptance Corp is a consumer finance company that specializes in automobile loans. These loans are offered through a U.S. nationwide network of automobile dealers that benefit from sales of vehicles to consumers who could otherwise not obtain financing. The company also benefits from repeat and referral sales, and from sales to customers responding to advertisements for financing, but qualify for traditional financing. The company derives its revenue from finance charges, premiums earned on the reinsurance of vehicle service contracts, and other fees. Of these, financing charges, including servicing fees, are by far a source of revenue.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.